Humans are infected by Mycobacterium tuberculosis (MTB), the cause of tuberculosis (TB), primarily by inhaling aerosolized bacteria. Most individuals require adaptive T cell immunity to control MTB. The hallmark of this host-pathogen interaction is that, despite T cell immunity's control of bacillary growth, T cells do not eradicat MTB. Thus T cells and infected antigen presenting cells (APC) are not only central for control of MTB but also targets of its immune evasion strategies. Our studies have demonstrated that MTB interferes with T cell recognition of infected cells. We have used a strategy starting with MTB fractions followed by purification of MTB molecules that directly affect T cell function or antigen processing. Once an MTB molecule is identified, the molecular mechanism is determined. To date, we have identified 4 MTB mechanisms that affect T cell function: 2 inhibit and 2 activate human T cells. PIM and Rv2468c interact with VLA-5 on T cells to induce adhesion to fibronectin; lipoproteins can co-stimulate T cells through TLR-2. In contrast MTB lipoproteins through TLR-2 inhibit MHC-II antigen processing by macrophages; and (our most recent discovery) ManLAM inhibits proximal T cell receptor signaling (TCR) in a TLR-2 independent manner. Inhibition of TCR signaling by ManLAM, the most recent mechanism that we have discovered, forms the focus of this competing renewal application for the following reasons. First, ManLAM is one of the most abundant glycolipids in the MTB cell wall. Second, ManLAM travels outside the phagosome to interact with host cells. Third, ManLAM is readily found in exosomes and microvesicles produced by MTB infected cells, providing a mechanism for direct delivery to T cells. Fourth, ManLAM inserts into host cell membranes. Fifth, ManLAM represents the most direct mechanism so far for interdicting T cell response during both latent MTB infection and active TB. Thus ManLAM's interference with TCR signaling represents a second major mechanism for interfering with T cell activation and that sensitivity to this inhibitoy effect may affect one's ability to control or eliminate latent bacilli. The aims are: Aim 1. To determine the molecular mechanism of inhibition of TCR signaling by ManLAM in terms of how ManLAM is delivered to T cells, how and where it inserts in the T cell membrane and how it interferes with TCR function and T cell-APC conjugate formation, and ManLAM's structural requirements for inhibition. Aim 2. To determine the functional consequences of ManLAM inhibition of CD4+ T cell activation in terms of recovery of inhibition, induction of apoptosis or anergy, differential effects on non-CD4+ T cells and synergy with inhibition of MHC-II antigen processing. Aim 3. To determine the ability of ManLAM to inhibit T cell responses to MTB in vivo using the murine MTB infection model and determining if there is variable sensitivity to ManLAM among humans.
NIH ExPorter
NIH ExPorter